ROCHE HOLDING AG
RHHBYLoading price...
Overview
Previous Close54.64
Open55.42
Ask54.63
Bid54.60
Day's Range54.46 - 55.42
52 Week Range37.51 - 60.85
PE Ratio(TTM)23.13
Market Cap347.96B
Volume12.67k
Avg. Volume2.11M
12 Months Earnings12.34B
12 Months Revenue62.96B
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|---|
| Operating Revenue | 62.96B | 63.36B | 62.40B | 60.44B | 65.81B | |
| Cost of Revenue | 16.62B | 16.64B | 16.28B | 16.28B | 16.36B | 19.74B |
| Gross Profit | 46.34B | 46.71B | 46.11B | 44.08B | 46.08B | |
| Operating Expenses | 28.52B | 28.23B | 32.70B | 32.70B | 28.69B | 28.60B |
| Profit after Tax (Net Income) | 12.34B | 12.88B | 8.28B | 8.28B | 11.50B | 12.42B |
Company Profile
Sector: Healthcare
Industry: Drug Manufacturers - General
HQ Location: Basel, Switzerland
Website: https://www.roche.com
Executive Chairman: Dr. Severin Schwan Ph.D.
About Company:
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.